• Scientific Publications
• eProtein Newsletters
• Annual Reports
• CPTC Patient Brochure
• Proteomics Primer
• Video Tutorial
• Pioneers of Proteomics
• Glossary

Pioneers of Proteomics

The Pioneers of Proteomics video series presents leaders in the field of proteomics discussing recent developments in the field, the inherent challenges in studying proteins and significant opportunities afforded by this rapidly evolving field.

	Gilbert Omenn, M.D., Ph.D. Dr. Omenn is Professor of Internal Medicine, Human Genetics, and Public Health at the University of Michigan. He served as Executive Vice President for Medical Affairs and as Chief Executive Officer of the University of Michigan Health System from 1997-2002. He is principal investigator of the Michigan Life Sciences Corridor Proteomics Alliance for Cancer Research program and leader of the international Human Proteome Organization (HUPO) Human Plasma Proteome Project. Dr. Omenn discusses the challenges of studying proteins, the validation of biomarkers for the clinic and the need to personalize medicine. Click here to view video.
	Richard Caprioli, Ph.D. Dr. Caprioli is the Stanley Cohen Professor of Biochemistry and Director of the Mass Spectrometry Research Center at Vanderbilt University School of Medicine. He is also currently Professor in the Departments of Chemistry and Pharmacology at Vanderbilt University. Dr. Caprioli’s lab is focused on the development of new mass spectrometry and data analysis techniques. His laboratory is a pioneer in imaging mass spectrometry (IMS) which enables direct profiling of proteins in sectioned tissue. Dr. Caprioli discusses imaging mass spectrometry and its application to cancer and personalized medicine as well as the need for continuous innovation and a multidisciplinary approach. Click here to view video.
	Catherine Fenselau, Ph.D. Dr. Fenselau is Professor of chemistry and biochemistry at the University of Maryland and is past president of the American Society for Mass Spectrometry, a member of the executive committee of the U.S. Human Proteome Organization and associate editor of the ACS journal Analytical Chemistry. Dr. Fenselau was one of the first trained mass spectroscopists to take a faculty position in a U.S. medical school. Dr. Fenselau discusses the application of proteomics to the study of drug resistance and the requirements for continued advancement in proteomics. Click here to view video.
	Ruedi Aebersold, Ph.D. Ruedi Aebersold, Ph.D. is co-founder of the Institutes for Systems Biology in Seattle and Professor of Systems Biology, Institute of Biotechnology, ETH-Zurich and Faculty of Natural Sciences, University of Zurich. Dr. Aebersold discusses the application of mass spectrometry to the field of proteomics and the need for sample quality control, data sharing and improvements in instrumentation and reagents. Click here to view video.
	Stanley Hefta, Ph.D. Stanley Hefta, Ph.D. is Executive Director of Proteomics in the Departments of Applied Genomics and Clinical Discovery at Bristol-Myers Squibb. Dr. Stanley Hefta discusses the challenges of identifying biomarkers amongst highly abundant proteins, the need to create standard practices between laboratories, and the promising future of proteomics. Click here to view video.
	John Yates, Ph.D. Dr. Yates is Professor of Cell Biology and Head of the Proteomics Mass Spectrometry Lab at the Scripps Research Institute. In addition to proteomics, Dr. Yates' research interests include the development of integrated methods for tandem mass spectrometry analysis of protein mixtures and bioinformatics using mass spectrometry data. Dr. Yates discusses the latest trends in mass spectrometry, requirements for continued advancement in the field of proteomics, and the impact of proteomics in the clinic. Click here to view video.
	Joshua LaBaer, M.D., Ph.D. Dr. LaBaer is Director of the Harvard Institute of Proteomics at Harvard Medical School. He is currently an Attending Physician at the Dana-Farber Cancer Institute and holds an academic appointment through the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Dr. LaBaer discusses the factors critical to advancing the field of proteomics and the challenges of applying proteomics to cancer diagnosis and treatment. Click here to view video.
	Mark Boguski, M.D., Ph.D. An expert in bioinformatics, Dr. Boguski is a founder of the integrated program in genome and proteome sciences at the Novartis Institutes for BioMedical Research (NIBR), overseeing the interface of genomic services with disease areas and platforms. Dr. Boguski discusses the challenges of proteomics research and its application in the clinical setting. Click here to view video.
	Leland Hartwell, Ph.D. Dr. Hartwell is president and director of the Fred Hutchinson Cancer Research Center, and recipient of the 2001 Nobel Prize in Physiology or Medicine for his pioneering work in yeast genetics. Dr. Hartwell discusses clinical proteomic technologies and cancer biomarker discovery. Click here to view video.

A Service of the National Cancer Institute